Lipocalin 2 (LCN2)

Overview

Lipocalin 2 (LCN2), also known as neutrophil gelatinase-associated lipocalin (NGAL), is a secreted lipocalin-family protein with important roles in inflammation, tissue injury responses, and metabolic regulation. It is widely studied as a biomarker of kidney injury, but it is also increasingly recognized as a biologically active mediator rather than only a passive marker. In disease settings, LCN2 is often induced by inflammatory stimuli and stress signals, including bacterial lipopolysaccharide, high glucose, and other injury-associated cues.

Beyond its established use in renal research, LCN2 has been implicated in metabolic dysfunction associated steatotic liver disease, Metabolic dysfunction associated steatohepatitis (MASH), muscle atrophy, and neuroinflammatory responses. Recent studies also connect LCN2 with pathways involving IL-6, iNOS, PPARα activation, oxidative stress, and renal tubular injury markers such as KIM-1. These findings support a broader view of LCN2 as a stress-responsive mediator linking inflammation, organ injury, and systemic metabolic disease.

Recent Publications Summary

Recent studies have continued to evaluate Lipocalin 2 (LCN2) as a biomarker and mechanistic target across inflammatory, renal, and metabolic disease contexts. In pediatric inflammatory bowel disease, fecal LCN2 was significantly elevated compared with acute diarrhea and healthy controls, and it correlated with disease duration, C-reactive protein, and Crohn’s Disease Activity Index, with the strongest correlation among the tested fecal markers for Crohn’s disease activity 42464159Jul. In Chagas disease, urinary and blood biomarker profiling included NGAL, a lipocalin family member, as part of an effort to detect early renal and endothelial dysfunction across acute and chronic phases, although routine renal function tests remained within normal ranges in the reported cohort 42467670Jul. A separate biomarker platform study also highlighted NGAL as a highly sensitive clinical protein target for ultrasensitive immunodetection, underscoring the broader diagnostic interest in lipocalin-family proteins 41655520Feb.

LCN2 has also emerged as a disease-modifying factor in inflammatory and metabolic tissue injury. In metabolic dysfunction-associated steatohepatitis, integrative mouse and human transcriptomic/proteomic analyses identified LCN2 as one of three MASH-induced hepatokines elevated in circulation in sarcopenic mouse models and in sarcopenic patients with advanced chronic liver disease 42270040Jun. Recombinant LCN2, like LGALS3, induced atrophy in C2C12 myotubes, and liver-secreted proteins altered mitochondrial metabolism in myotubes, linking LCN2 to muscle wasting in the setting of liver disease 42270040Jun. In asthma, PM2.5 exposure was shown to activate the Fra2/LCN2 axis, promoting ferroptosis in M2 macrophages; macrophage-specific LCN2 knockdown in mice attenuated this pathway, supporting a functional role for LCN2 in pollutant-aggravated airway inflammation 42214888May.

Functional genomics and delivery studies have further used LCN2 as an experimental target. An optimized lipid nanoparticle platform enabled efficient CRISPR/Cas9 knockout of LCN2 in MDA-MB-231 cells, producing a 90.8% reduction in LCN2 mRNA and inhibiting cell proliferation and migration, demonstrating the feasibility of targeting LCN2 with genome editing approaches 42214710May. Together, these publications position LCN2 as both a clinically informative biomarker and a biologically active mediator in inflammatory, metabolic, and environmental disease processes 42464159Jul42270040Jun42214888May42214710May.

What Changes, What Holds

1. LCN2 is gaining traction as a disease-linked biomarker beyond kidney injury, but the new uses are still context-specific
NEW DIRECTION Fecal and blood/urine profiling extend lipocalin 2/NGAL into inflammatory bowel disease and Chagas disease surveillance, while the ultrasensitive immunodetection work mainly strengthens its practicality as a measurable target 42464159Jul42467670Jul41655520Feb. This does not displace the established kidney-injury role; it broadens the settings in which LCN2 may be clinically informative, with the strongest immediate implication being biomarker expansion rather than a new mechanism.

2. LCN2 now looks like an active driver of tissue wasting and pollutant-aggravated airway injury
NEW DIRECTION The MASH/sarcopenia findings add a disease-modifying role that goes beyond the Overview’s inflammation and metabolic-regulation framing, because LCN2 is not just associated with injury but can promote muscle atrophy in that setting 42270040Jun. The asthma study similarly places LCN2 in a mechanistic axis linking particulate exposure to ferroptotic macrophage injury 42214888May. Together, these results widen LCN2 from a stress marker to a mediator of organ cross-talk and environmental damage.

3. LCN2 is becoming a tractable experimental target for direct genetic suppression
METHOD CRISPR/Cas9 knockout delivered by an optimized lipid nanoparticle platform shows that LCN2 can be efficiently edited in cells and that loss of expression alters proliferation and migration 42214710May. This changes how the protein can be studied and potentially targeted, but it does not revise the biological roles already in the Overview; it mainly supplies a new intervention and measurement strategy for testing causality.

Overview update candidates: LCN2 as a biomarker in inflammatory bowel disease and Chagas-related renal/endothelial screening; LCN2 as a mediator of muscle atrophy in MASH/sarcopenia and of PM2.5-aggravated airway inflammation; LCN2 as a feasible direct genome-editing target.